- Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe - Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026 - Capability to obtain market approval is further strengthened with the appointment of Rob Eyers as Chief...
Read More Details
Finally We wish PressBee provided you with enough information of ( Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval )
Also on site :
- ‘This is murder': Family remembers victims killed in Austin fire as 4th body recovered
- RHOM star Larsa Pippen got ‘boob job, nose job, BBL and fillers’ to look like a ‘doll,’ top plastic surgeon claims
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, NVEE, SOAR, PLL on Behalf of Shareholders